Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - (A) Update On Resignation Of Company Secretary & Compliance Officer (B) Appointment Of Compliance Officer
In furtherance to our letter dated February 14, 2023 we wish to inform you that the Board of Directors vide their resolution dated March 21, 2023 have: a) Noted the resignation of Mr. Rajat Kalra as Company Secretary & Compliance Officer of the Company. His last working day will be March 31, 2023 (Closing of business hours); b) Approved the appointment of Mr. Vinay Gujral (ACS 25995) as Compliance Officer of the Company with effect from April 01, 2023. The disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as 'Annexure -A'.
Are healthcare stocks attractive now? Brokerages recommend these shares to buy or sell
For Dr Lal Pathlabs, Kotak Institutional Equities maintained a bearish stance, reiterating the downside risk to their flat long-term pricing assumptions Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
In furtherance to Company''s letters dated February 03, 2020, February 11, 2020 and May 13, 2022 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon''ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench-Il has, vide its order dated March 17, 2023, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('Transferee Company') and APL Institute of Clinical Laboratory & Research Private Limited ('Transferor Company'), a wholly owned subsidiary of Transferee Company. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Intimation Of Results Of Postal Ballot
We wish to inform you that the Shareholders of the Company have approved the following Special Resolution(s) through Postal Ballot w.e.f. March 10, 2023: 1. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Independent Director of the Company 2. Payment of commission to Mr. Arun Duggal (DIN: 00024262) as an Independent Director of the Company In this regard, please find enclosed the following documents: 1. Details of the voting results in prescribed format as required under Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - 1. 2. Report of the Scrutinizer on e-Voting results as Annexure - 2. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s).